What BioRay Biotech does

BioRay Biotech (光晟生技 / 光晟生物科技股份有限公司) is a privately-held Taiwanese bio-pharmaceutical company founded in 2005 and headquartered in the Tainan Southern Science Industrial Park (manufacturing operations in Pingtung Agricultural Biotechnology Park). The company operates three intertwined business lines: (1) Precision Medical Testing services spanning Oncology Profile (NGS + LC-MS/MS + PCR), Gut Microbiome analysis, Immune Profile (flow cytometry), and an integrated Health Insights offering; (2) CIK (Cytokine-Induced Killer) immune cell therapy, manufactured at Taiwan FDA GTP-certified facilities (Tainan TP110C026, Kaohsiung TP112C033) and delivered through five named Taiwan hospital partners including Chi Mei Medical Center and Gaohe Hospital, with reported outcomes of 99.9% cell purity, 82% NK-cell activity enhancement in three-year follow-up, and 500+ stage IV solid tumor patients treated; (3) Health supplements, sold both as proprietary consumer brands (Haokang Probiotics / 好康益生菌, Tanganding PLUS, Gulijie, Yilushui, Cordyceps lines) and via ODM/OEM contract manufacturing for 20+ domestic and international brands using its patented micro-pellet formulation technology and patented probiotic strains. Annual raw material exports exceed 5 tons and one partner brand's BR022-based product has surpassed 500,000 boxes in annual sales.

Name

BioRay Biotech

Legal name

光晟生物科技股份有限公司

Website

https://bio-ray.com.tw

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

BioRay Biotech is a Taiwanese bio-pharmaceutical company that develops patented probiotic strains, GTP-certified CIK immune cell therapy, and precision medical testing services for hospitals, health-conscious consumers, and health supplement brands preparing for Taiwan OTC listing.

Ownership category

akta.pro rank

Product category

Bio-pharmaceutical Probiotics and Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Probiotics & Digestive Health Supplements (CRADAGAF)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Probiotic strain development
• Cell therapy services
• Precision medical testing
• Health supplement manufacturing
• ODM/OEM contract manufacturing

Headquarters

HQ city

Pingtung

HQ country

Taiwan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Health Supplement Sales (Own Brands): Sales of proprietary health supplement products under the BioRay brand, including probiotics, cordyceps, and functional health products through direct sales and retail channels.
2. ODM/OEM Contract Manufacturing: Custom formulation, manufacturing, and branding services for B2B partners seeking to incorporate BioRay's patented probiotic strains and micro-pellet technologies into their own health supplement brands. Contributes 60% of revenue from own brands and 30% annual growth from B2B raw material exports.
3. CIK Immune Cell Therapy: GTP-certified CIK cell preparation and related cell therapy services provided in partnership with hospitals, serving as a cell product supplier for clinical applications under Taiwan FDA regenerative medicine regulations.
4. Precision Medical Testing Services: Comprehensive health testing services including cancer risk assessment, immune function analysis, gut microbiome and nutritional analysis, and holistic health data insights, offered to individuals and through hospital partnerships.
5. Patented Raw Material Licensing: Export and licensing of internationally patented probiotic strains and fermentation technologies to international brands, with partnerships including over 20 domestic and international brands and annual export exceeding 5 tons.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

BioRay Biotech researches, develops, manufactures, and distributes bio-pharmaceutical products spanning three integrated business lines: (1) precision medical testing services including cancer risk assessment, immune function analysis, gut microbiome analysis, and holistic health data insights built on six integrated technology platforms; (2) CIK (Cytokine-Induced Killer) immune cell therapy services delivered through GTP-certified facilities and partner hospitals for solid tumor patients; and (3) branded and ODM/OEM health supplement products based on 17 patented probiotic strains, Cordyceps militaris, Antrodia cinnamomea, and patented micro-pellet formulation technology.

Product overview

BioRay Biotech offers a unified precision medicine platform combining three core service areas: (1) Precision Medical Testing — including Oncology Profile, Gut Microbiome, Immune Profile, and Health Insights services that integrate six technology platforms (Flow Cytometry, NGS, Microfluidic Chip, LC-MS/MS, Real-Time PCR, Qubit Fluorometer) for comprehensive health assessment; (2) CIK Immune Cell Therapy — GTP-certified cell preparation and treatment services for cancer patients with stage I-IV solid tumors, developed through collaborations with Chi Mei Hospital and Gaohe Hospital; and (3) Health Supplements — ODM/OEM manufacturing services and proprietary branded products featuring patented probiotic strains (BRAP-01, BR-022, BR-0121), Cordyceps militaris with 29x cordycepin content, Antrodia cinnamomea, and patented micro-pellet drug delivery technology. The company operates a Taiwan FDA GTP-certified cell preparation facility and provides testing services to external clients.

Differentiator

Problem solved

Functional benefit

Brands

• 好康益生菌 (Haokang Probiotics): Nationally certified health food with dual efficacy for allergic constitution adjustment and gastrointestinal function improvement
• 古力捷 (Gulijie)
• 田甘定 PLUS (Tanganding PLUS)
• 益路水 (Yilushui)
• 好益活 (Haoyihuo)

Products and services

• Oncology Profile (癌症風險評估) Precision cancer risk assessment combining Next-Generation Sequencing (NGS), Liquid Chromatography-Mass Spectrometry (LC-MS/MS), and real-time PCR to analyze genes, metabolites, and circulating cell-free DNA for early cancer risk detection in individuals and hospital-referred patients.
• Gut Microbiome Analysis (腸道菌相與營養分析) Integrated gut microbiota and nutritional metabolism analysis using NGS and LC-MS/MS to assess intestinal barrier integrity and provide personalized dietary and probiotic recommendations for health-conscious individuals and clinical patients.
• Immune Profile (免疫功能分析) Functional immune analysis focusing on immune cell subpopulation composition and cellular combat power quantification beyond traditional cell count measurements, performed at Taiwan FDA LDTS-certified laboratory (LDT0005).
• Health Insights (全方位健康數據洞察) Comprehensive health data analysis integrating six technology platforms (Flow Cytometry, NGS, Microfluidic Chip, LC-MS/MS, Real-Time PCR, Qubit Fluorometer) to generate personalized health blueprints with actionable recommendations.
• CIK Immune Cell Therapy (CIK免疫細胞治療) Cytokine-Induced Killer (CIK) immune cell therapy for cancer adjunctive treatment, enhancing immune cell killing power through induced proliferation and activation for stage I-IV solid tumor patients. Delivered through partner hospitals including Chi Mei Medical Center and Gaohe Hospital; over 500 stage IV solid tumor patients treated.
• Patented Probiotic Raw Materials and Ingredients (專利原料) Proprietary patented probiotic strains and functional ingredients sold as raw materials to health supplement brands globally. Includes BRAP-01 (82% allergy regulation efficacy), BR-022 (90%+ intestinal relief within 7 days), BR-0121 (metabolic regulation), Cordyceps militaris (29x wild cordycepin), and Antrodia cinnamomea. Annual raw material exports exceed 5 tons to over 20 brands.
• BioRay Product Portfolio (光晟系列產品) Branded health supplement product portfolio targeting children, adults, seniors, and women. Includes Haokang Probiotics (nationally certified health food, 衛署健食字第A00201號), Gulijie (senior bone health), Tanganding PLUS (metabolic regulation built on BR-0121), Yilushui (senior health), and Haoyihuo (premium senior brand using BR022 strain formulation, >500,000 boxes sold annually).
• GTP Cell Preparation Facility Service (GTP等級細胞製備場所) GTP-certified cell preparation facility providing contract development and manufacturing services for cell therapy products, with capabilities including sterility, mycoplasma, and endotoxin testing under Taiwan FDA recognition (TP110C026 Tainan Plant; TP112C033 Kaohsiung Plant).
• ODM/OEM Health Supplement Manufacturing (專業代工ODM/OEM) Original design and manufacturing services for health supplements, offering exclusive patented raw materials (BRAP-01, BR-022, BR-0121, Cordyceps, Antrodia), full dosage form production including patented micro-pellet formulations, and packaging design for brand partners.

Quantifiable outcome

• Over 500 stage IV solid tumor patients treated with CIK cell therapy
• +8 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Probi AB: Swedish global leader in probiotic R&D and B2B ingredient licensing with clinically documented Lactobacillus strains. Comparable as a probiotic IP licensor selling patented strains into supplement and functional food brands worldwide.
• Lonza Group: Global contract development and manufacturing organization (CDMO) for biologics and cell & gene therapies. Comparable as a provider of GMP/GTP-equivalent cell therapy manufacturing services, though at much larger scale.
• Yakult Honsha: Global probiotic dairy and supplement brand built on proprietary Lactobacillus strain science (Shirota strain). Comparable as a vertically integrated probiotic IP owner with branded consumer products and B2B licensing.
• Chr. Hansen (now Novonesis): Global bioscience major with one of the world's largest commercial probiotic strain libraries and B2B ingredient supply across food, supplement, and animal health. Comparable as a scale probiotic raw-material and culture supplier competing for the same brand customers.
• Kerry Group: Global taste and nutrition company with a major probiotic and postbiotic ingredient business serving supplement, dairy, and functional food brands. Comparable as a large-scale buyer of probiotic technology and competitor for branded health-supplement customers.

Direct peers

• SunWay Biotech: Taiwan-based biotech active in immune cell therapies (including CIK/DC-CIK) and precision testing. Closely comparable to BioRay's CIK cell therapy and precision testing service lines.
• GenMont Biotech: Taiwan-based probiotic and functional ingredient manufacturer with patented Lactobacillus strains and ODM/OEM services. Highly comparable to BioRay's supplement franchise, including strain bank ownership and international B2B raw material exports.
• TCI Bio: Taiwan nutraceutical/functional food contract manufacturer with ODM/OEM capabilities and proprietary ingredient IP. Comparable as a Taiwanese health-supplement ODM competitor with patented raw materials.
• Grape King Bio: Taiwan-listed health supplement and probiotic company combining proprietary fermentation with branded products and OEM services. Closely comparable in business model (probiotics + health foods + ODM) and target customer base.

Regional players

• PharmaEssentia: Taiwan-listed biopharmaceutical company developing biologic drugs (notably ropeginterferon). Comparable as a Taiwan biotech pursuing international commercialization of a proprietary biologic, though focused on oncology/inflammation rather than probiotics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioRay Biotech